1. Home
  2. > Pharmaceutical
  3. > Generic Drug Market Trends
Generic Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Generic Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • March 2022
  • 156 pages
  • ID: 6246254
  • Format: PDF
  • Mordor Intelligence LLP

Summary

Table of Contents

Search Inside

The generic drugs market was valued at USD 364,925.27 million in 2021, and it is expected to reach USD 468,787.86 million by 2027, registering a CAGR of 4.27% during the forecast period of 2022-2027.

During the early pandemic, COVID-19 has severly impacted the generic drugs market due to the lockdown restrictions and supply chain disruption. Later, there has been increased demand for the generic pharmaceuticals as the COVID-19 infections has provided many opportunities for the generic drug manufacturers to manufacture the drugs for the treatment of this infection. For instance, According to a report by United States Food and Drug Administration (FDA) in published in November 2021, FDA has implemented a Generic Drug Program. This initiative assisted generic medication developers with product development by sending written communications and holding meetings to clarify regulatory expectations early in the development process and during application review. By this Food and Drug Administration received 121 requests for product development and pre-submission pre-Abbriviated New Drug Application meetings in 2020.

As the global generic drugs market is huge, it is very likely to continue growing in the forecast period. The reasons attributed for this growth are the increasing prevalence of chronic diseases, increase in the geriatric population, and increasing healthcare expenditure.

Many North American and Asia-Pacific countries are facing the issue of the rise in the geriatric population, which is also expected to increase the demand for generic drugs, as older people need more drugs because of comorbidities and other factors. Due to the prevalence of chronic disorders, the government and many pharmaceutical players are increasing their expenditure in R&Ds for the discovery of new molecules and enhancing the current technologies so that more patient issues can be addressed. For instance, according to the International Diabetes Federation, in 2021, approximately 537 million adults (20-79 years) are living with diabetes across the globe and the total number of people living with diabetes is projected to rise to 643 million by 2030 and 783 million by 2045.

Hence, based on the aforementioned factors, the market is expected to grow significantly during the forecast period.

Key Market Trends

Injectable Segment is Expected to Witness a Major Share in the Studied Market Over the Forecast Period

Tablets, capsules, pills are not the only way to administer the drug in the body, the injectable is another way of administration of the drug, and this is considered to be the most effective way, as the bioavailability of the drug through this route is higher than the other routes. Nowadays, new advancements are happening in this injectable segment. Through this route, the drug takes less time to react. Recent developments in needle-free injectors have helped its growth. For instance, In November 2021, Bespak Europe Limited works closely with its biopharmaceutical partners to develop a customized device for the needs of specific patient groups. Moreover, the prevalence of diabetes, cardiovascular problems, cancer, and several other chronic diseases will help the injectables to grow more in the forecast period.

Furthermore, rising intravenous generic product launches is further expected to drive the growth of this segment in the forecast period. For instance, in July 2021, Generic Ferumoxytol, an injectable drug used to treat iron deficiency anaemia (IDA) has launched in the United States by Sandoz, a global leader in generic and biosimilar medicines. The rise in product launches of injectable generic products in the developed countries is further expected to drive the growth of this segment in the near future.

Asia Pacific is the Fast Growing Region in Overall Market and Similar is Expected Over the Forecast Period.

Asia-Pacific has shown the fastest growing trend in the global generic market owing to increased awareness among the people related to any disorder, the rise in population can also be attributed to the increase in demand for generic drugs. Countries like India and China in Asia-Pacific contribute more than the other nations.

According to the Indian Pharmaceutical Industry Report published in November 2021 by India Brand Equity Foundation, India is the world’s top supplier of generic pharmaceuticals. The Indian pharmaceutical industry supplies more than half of global demand for vaccines, 40% of generic demand in the United States, and 25% of all pharmaceuticals in the United Kingdom. Indian has many pharmaceutical companies that manufacture many generic drugs, e.g., Alkem Laboratories, Sun Pharma, Aurobindo Pharma Limited, among several others. Hence, the market for global generic drugs is likely to grow in the forecast period.

Furthermore, according to the news published in September 2021, India is open to working with East Asian partners on the development of generic pharmaceuticals and medical technology for the treatment of Covid-19 patients, as well as vaccine development. This will further lead to increase in production of generic drugs in collaboration with other East Asian companies, thereby expected to propel the market growth over the forecast period.

Moreover, the rising approvals of generic drugs in China is further expected to drive this regions growth. For instance in October 2021, The Yangtze River Pharmaceutical Group in China has submitted the first marketing application for eslicarbazepine acetate, a class 3 generic medication used to treat epileptic patients.

Therefore, owing to the above mentioned factors, the Asia Pacific region is expected to show growth at larger pace over the forecast period.

Competitive Landscape

The Global Generic Drugs Market is highly competitive, with many players dominating the market. The market players are adopting strategies such as rising R&D investment, mergers, acquisitions, and product innovations, in order to sustain the increasing market rivalry. The key market players in this market include Mylan NV, Eli Lilly and Company, GlaxoSmithKline PLC, Pfizer Inc., Sun Pharma, Novartis, and Sanofi, among others.

Additional Benefits:

The market estimate (ME) sheet in Excel format
3 months of analyst support

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Generic Pharmaceuticals Global Market Opportunities And Strategies To 2030: COVID-19 Impact And Recovery

  • $ 5000
  • June 2022
  • 305 pages

Generic Pharmaceuticals Global Market Opportunities And Strategies To 2030: COVID-19 Impact And Recovery provides the strategists; marketers and senior management with the critical information they need ...

  • World
  • Generic Drug
  • Industry analysis
  • Gross Domestic Product Per Capita
  • Health Expenditure

ref:plp2022

Reportlinker.com © Copyright 2023. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on